Showing 3541-3550 of 4062 results for "".
- US to Buy 500 Million Doses of Pfizer, BioNTech COVID-19 Vaccine for Donation to Poorest Nationshttps://modernod.com/news/us-to-buy-500-million-doses-of-pfizer-biontech-covid-19-vaccine-for-donation-to-poorest-nations/2479284/Pfizer and BioNTech said Thursday that they will provide 500 million doses of the COVID-19 vaccine BNT162b2 to the US government at a not-for-profit price to support immunization programs in low- and lower-middle-income countries, according to FirstWord. The companies noted that 200 million doses
- Ocuphire Added to the Russell Microcap Indexhttps://modernod.com/news/ocuphire-added-to-the-russell-microcap-index/2479285/Ocuphire Pharma announced that the company is set to join the Russell Microcap Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, 2021, according to a preliminary list of additions posted June 4, 2021. Membership in th
- Iveric Bio to Host Investor Symposium on Dry AMDhttps://modernod.com/news/iveric-bio-to-host-investor-symposium-on-dry-amd/2479282/Iveric bio announced details for its Dry Age-Related Macular Degeneration Virtual Symposium for investors and analysts being held on Friday, June 18, 2021 from 10 am to 12 pm Eastern Time. The symposium will include presentations on the company’s Zimura (avacincaptad pegol) pivotal program in geo
- Ocuphire Announces Appointment of Jay S. Pepose, MD, PhD, to Its Board of Directorshttps://modernod.com/news/ocuphire-announces-appointment-of-jay-s-pepose-md-phd-to-its-board-of-directors/2479272/Ocuphire Pharma announced the appointment of Jay S. Pepose, MD, PhD, to its Board of Directors. Concurrent to Dr. Pepose’s appointment at Ocuphire’s annual shareholder meeting on June 7, Alan Meyer, MBA, retired from his role on the Board of Directors, having served since April 2018. “We a
- International Sports Vision Association and Macuhealth Offer New Educational Resource on Sports Nutrition for Your Eyeshttps://modernod.com/news/international-sports-vision-association-and-macuhealth-offer-new-educational-resource-on-sports-nutrition-for-your-eyes/2479270/The International Sports Vision Association (ISVA) and MacuHealth announced the launch of “Sports Nutrition for Your Eyes,” a new educational resource on the ISVA website designed to help educate athletes about how proper nutrition ca
- Even Inactive Thyroid Eye Disease Adversely Impacts Patientshttps://modernod.com/news/even-inactive-thyroid-eye-disease-adversely-impacts-patients/2479264/Ocular signs and symptoms of thyroid eye disease (TED) often persist beyond the active phase of the condition, with many patients continuing to experience mental health issues and diminished quality of life, new research suggests, as reported<
- Kala Pharmaceuticals Announces Eysuvis Now Covered by OptumRxhttps://modernod.com/news/kala-pharmaceuticals-announces-eysuvis-now-covered-by-optumrx/2479263/Kala Pharmaceuticals announced that OptumRx, one of the largest pharmacy benefit managers (PBM) in the United States, has added Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies, effective May 21, 2021. “We are pleased to announce
- Sai Chavala, MD, Receives ARVO Foundation Ludwig Von Sallmann Clinician-Scientist Awardhttps://modernod.com/news/sai-chavala-md-receives-arvo-foundation-ludwig-von-sallmann-clinician-scientist-award/2479262/CiRC Biosciences Co-Founder and Chief Scientific Officer Sai Chavala, MD, has been awarded the 2021 Ludwig von Sallmann Clinician-Scientist Award from the Association for Research in Vision and Ophthalmology (
- Nanoscope’s Optogenetic Gene Therapy Restores Clinically Meaningful Vision in 11 Patients Blinded by Retinitis Pigmentosahttps://modernod.com/news/nanoscopes-optogenetic-gene-therapy-restores-clinically-meaningful-vision-in-11-patients-blinded-by-retinitis-pigmentosa/2479261/Nanoscope Therapeutics announced that vision improvements for all evaluated advanced retinitis pigmentosa (RP) patients persisted through 1 year following a single intravitreal injection in a phase 1/2a clinical study with MCO. “We expect to begin the first randomized, placebo-contro
- Salvat Completes Phase 3 Clinical Trials of its New Ophthalmic Corticosteroid Nanoemulsionhttps://modernod.com/news/salvat-completes-phase-3-clinical-trials-of-its-new-ophthalmic-corticosteroid-nanoemulsion/2479254/Salvat has completed the phase 3 clinical trials in the US for its drug candidate for the treatment of ocular inflammation and pain after cataract surgery. The clinical trials started in 2020 and include 400 adult patients who had recently undergone cataract surgery in 50 US hospitals. Res